SwePub
Sök i LIBRIS databas

  Extended search

onr:"swepub:oai:gup.ub.gu.se/305186"
 

Search: onr:"swepub:oai:gup.ub.gu.se/305186" > No association betw...

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist
  • Nielsen, S. N.Univ Copenhagen, Denmark (author)

No association between relapse hazard and thiopurine methyltransferase geno- or phenotypes in non-high risk acute lymphoblastic leukemia: a NOPHO ALL2008 sub-study

  • Article/chapterEnglish2021

Publisher, publication year, extent ...

  • 2021-04-29
  • Springer Science and Business Media LLC,2021

Numbers

  • LIBRIS-ID:oai:gup.ub.gu.se/305186
  • https://gup.ub.gu.se/publication/305186URI
  • https://doi.org/10.1007/s00280-021-04281-7DOI
  • https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-175696URI

Supplementary language notes

  • Language:English

Part of subdatabase

Classification

  • Subject category:ref swepub-contenttype
  • Subject category:art swepub-publicationtype

Notes

  • Funding Agencies|Danish Cancer SocietyDanish Cancer Society; Childhood Cancer Foundation (Denmark); Childhood Cancer Foundation (Sweden); Nordic Cancer Union; Otto Christensen Foundation; University Hospital Rigshospitale; Novo Nordic FoundationNovo Nordisk Foundation
  • Purpose 6-mercaptopurine(6MP)/methotrexate maintenance therapy is essential to reduce relapse of childhood acute lymphoblastic leukemia (ALL). Common germline variants in TPMT cause low activity of thiopurine methyltransferase (TPMT) and higher 6MP metabolite (TGN) levels. Higher levels of TGNs incorporated into DNA (DNA-TG) and low TPMT activity have previously been associated with a lower relapse risk. We explored if TPMT geno- or phenotype was associated with DNA-TG levels and relapse rate in NOPHO ALL2008. Methods TPMT genotype, repeated phenotyping, and DNA-TG measurements were collected in 918 children with non-high risk ALL (NOPHO ALL2008 maintenance therapy study). Maintenance therapy started with 6MP at 50 and 75 mg/m(2) for TPMT heterozygous and wildtype patients and was adjusted to a target WBC of 1.5 - 3.0 x 10(9)/L. Results Of 918 patients, 78 (8.5%) were TPMT heterozygous and 903 had at least one TPMT measurement (total 3063). Mean TPMT activities were higher with wildtype than heterozygous TPMT (N = 752, 16.6 versus 9.6 U/mL ery., p < 0.001). The 5-year cumulative incidence of relapse was 6.4% and 6.0% for TPMT heterozygous and wildtype patients, and there was no association between genotype and relapse rate (N = 918, hazard ratio = 1.01, 95% confidence interval [CI] 0.40 - 2.54, p = 0.98). Although TPMT heterozygous patients had higher DNA-TG (N = 548, median 760.9 [interquartile range (IQR) 568.7 - 890.3] versus 492.7 [IQR 382.1 - 634.6] fmol/mu g, p < 0.001), TPMT activity was not associated with relapse rate (N = 813; hazard ratio = 0.98 per one U/mL ery. increase in TPMT activity, 95% CI 0.91 - 1.06, p = 0.67). Conclusion TPMT geno- and phenotype were not associated with relapse in non-high risk NOPHO ALL2008.

Subject headings and genre

Added entries (persons, corporate bodies, meetings, titles ...)

  • Toksvang, L. N.Univ Copenhagen, Denmark (author)
  • Grell, K.Univ Copenhagen, Denmark; Univ Copenhagen, Denmark (author)
  • Nersting, J.Univ Copenhagen, Denmark (author)
  • Abrahamsson, Jonas,1954Gothenburg University,Göteborgs universitet,Institutionen för kliniska vetenskaper, Avdelningen för pediatrik,Institute of Clinical Sciences, Department of Pediatrics,Univ Gothenburg, Sweden(Swepub:gu)xabrjo (author)
  • Lund, B.Norwegian Univ Sci & Technol, Norway (author)
  • Kanerva, J.Univ Helsinki, Finland; Univ Helsinki, Finland (author)
  • Jonsson, O. G.Landspitali Univ Hosp, Iceland (author)
  • Vaitkeviciene, G.Vilnius Univ, Lithuania (author)
  • Pruunsild, K.Tallinn Childrens Hosp, Estonia (author)
  • Lindqvist Appell, MalinLinköpings universitet,Avdelningen för klinisk kemi och farmakologi,Medicinska fakulteten(Swepub:liu)malli06 (author)
  • Hjalgrim, L. L.Univ Copenhagen, Denmark (author)
  • Schmiegelow, K.Univ Copenhagen, Denmark; Univ Copenhagen, Denmark (author)
  • Univ Copenhagen, DenmarkUniv Copenhagen, Denmark; Univ Copenhagen, Denmark (creator_code:org_t)

Related titles

  • In:Cancer Chemotherapy and Pharmacology: Springer Science and Business Media LLC88, s. 271-2790344-57041432-0843

Internet link

Find in a library

To the university's database

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view